PDGFRB and ductal breast carcinoma in situ: Further evidence for PDGFRβ as a clinically relevant predictive biomarker has been obtained from post hoc analyses of tissue collections from two randomized adjuvant radiotherapy trials in DCIS and stage I/IIA breast cancer [97, 109].